Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is looking to hit the reset button with a new name and focus. Catabasis has been…
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
September 8, 8:05 AM
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc.
Wedbush Initiates Coverage On Catabasis Pharmaceuticals with Outperform Rating, Announces Price Target of $16
September 2, 7:07 AM
Wedbush analyst Laura Chico initiates coverage on Catabasis Pharmaceuticals (NASDAQ:CATB) with a Outperform rating and announces Price Target of $16.
August 25, 6:11 AM
HC Wainwright & Co. analyst Joseph Pantginis upgrades Catabasis Pharmaceuticals (NASDAQ:CATB) from Neutral to Buy and announces $13 price target.
August 24, 5:11 AM
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 7:45 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)
August 11, 5:02 PM